Climb Bio partner Mabworks doses first IgA nephropathy patient in Phase 2 China trial

Climb Bio, Inc.

Beijing Mabworks Biotech announced first patient dosed in Phase 2 trial for immunoglobulin A nephropathy in China.
Trial is conducted in collaboration with Climb Bio, Inc.; announcement made August 13, 2026.
Climb Bio disclosed the milestone via Form 8-K on August 14, 2026; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.